20.10.2016
Evotec AG DE0005664809
DGAP-News: EVOTEC AND UCB SIGN MULTI-YEAR CNS PHARMACOLOGY AGREEMENT
DGAP-News: Evotec AG / Key word(s): Alliance
EVOTEC AND UCB SIGN MULTI-YEAR CNS PHARMACOLOGY AGREEMENT
20.10.2016 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 20 October 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced a collaboration with UCB to provide a broad range of in vitro
pharmacology services.
Under the terms of the three-year agreement, Evotec will support UCB's in
vitro pharmacology team in drug discovery projects across multiple target
classes, particularly in the CNS space. Key activities will include assay
development, compound profiling and mechanistic studies and will provide
UCB with access to key Evotec expertise in the field of in vitro
pharmacology and electrophysiology.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Through
this significant collaboration focusing on CNS pharmacology, we continue to
strengthen our relationship with UCB, a strategic partner of Evotec. With
both teams already working closely together, we look forward to adding
value to UCB's drug discovery programmes."
Dr Neil Weir, Senior Vice President of Discovery at UCB, added: "Evotec has
demonstrated its scientific excellence and as such is a key partner
supporting our drug discovery efforts. We welcome the addition of CNS
pharmacology, where Evotec has specific expertise, to the range of
activities we collaborate on."
No financial details were disclosed.
ABOUT UCB
UCB is a global biopharmaceutical company with a portfolio of small
molecules and antibody based therapies for the treatment of severe
immune-mediated diseases and central nervous system disorders. UCB has over
7,700 employees worldwide with research and early development scientists
based in Belgium (Central Nervous System) and UK (immunology) supporting an
innovative pipeline of novel therapeutics. UCB's core products are treating
patients with epilepsy, rheumatoid arthritis and Parkinson's disease. UCB
recognises that the identification of new and innovative protein targets
remains a core challenge for the pharmaceutical industry. UCB therefore
continues to invest internally, externally and through collaboration to
ensure that we identify novel targets and mechanisms to tackle serious
diseases. For more information please visit: www.ucb.com.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer
in the field of tissue fibrosis. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
20.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
513009 20.10.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT